Literature DB >> 20207840

T-cell/histiocyte-rich large B-cell lymphoma.

Stefania Pittaluga, Elaine S Jaffe.   

Abstract

Mesh：

Year:  2010        PMID： 20207840      PMCID： PMC2833061          DOI： 10.3324/haematol.2009.016931

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  37 in total

1.  Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances.

Authors:  S Franke; I Wlodarska; B Maes; P Vandenberghe; J Delabie; A Hagemeijer; C De Wolf-Peeters
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

2.  The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease.

Authors:  E Torlakovic; A Tierens; H D Dang; J Delabie
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

3.  Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma.

Authors:  Sabine Franke; Iwona Wlodarska; Brigitte Maes; Peter Vandenberghe; Ruth Achten; Anne Hagemeijer; Chris De Wolf-Peeters
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

4.  Lymphocyte predominance Hodgkin's disease: the use of bcl-6 and CD57 in diagnosis and differential diagnosis.

Authors:  M D Kraus; J Haley
Journal:  Am J Surg Pathol       Date:  2000-08       Impact factor: 6.394

Review 5.  Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma.

Authors:  T Rüdiger; R D Gascoyne; E S Jaffe; D de Jong; J Delabie; C De Wolf-Peeters; S Poppema; L Xerri; C Gisselbrecht; S Wiedenmann; H K Müller-Hermelink
Journal:  Ann Oncol       Date:  2002       Impact factor: 32.976

6.  Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features.

Authors:  Ruth Achten; G Verhoef; L Vanuytsel; C De Wolf-Peeters
Journal:  Histopathology       Date:  2002-01       Impact factor: 5.087

7.  T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells.

Authors:  Megan S Lim; Michael Beaty; Lynn Sorbara; Richard Z Cheng; Stefania Pittaluga; Mark Raffeld; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2002-11       Impact factor: 6.394

8.  T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity.

Authors:  R Achten; G Verhoef; L Vanuytsel; C De Wolf-Peeters
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

9.  T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma.

Authors:  M Fraga; L Sánchez-Verde; J Forteza; A García-Rivero; M A Piris
Journal:  Histopathology       Date:  2002-09       Impact factor: 5.087

10.  Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma.

Authors:  Iwona Wlodarska; Peet Nooyen; Brigitte Maes; José I Martin-Subero; Reiner Siebert; Patrick Pauwels; Chris De Wolf-Peeters; Anne Hagemeijer
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113
View more
  11 in total

Review 1.  Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification.

Authors:  Elaine S Jaffe; Stefania Pittaluga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Diagnosis of Hodgkin lymphoma in the modern era.

Authors:  Hao-Wei Wang; Jayalakshmi P Balakrishna; Stefania Pittaluga; Elaine S Jaffe
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

Review 3.  The histological classification of diffuse large B-cell lymphomas.

Authors:  Yi Xie; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Hematol       Date:  2015-01-17       Impact factor: 3.851

4.  Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Jonathan A Trujillo; James Godfrey; Yifei Hu; Jun Huang; Sonali M Smith; Matthew J Frigault; Zachariah DeFilipp; Daniel Appelbaum; Yonglin Pu; Nicholas Feinberg; Thomas Althaus; Michael R Bishop; Peter A Riedell; Justin Kline
Journal:  Blood       Date:  2021-06-17       Impact factor: 22.113

5.  Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.

Authors:  Thomas A Ollila; John L Reagan; Adam J Olszewski
Journal:  Leuk Lymphoma       Date:  2019-07-09

Review 6.  Splenic Micronodular T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: The Corticosteroid Pretreatment Hypothesis.

Authors:  Benzion Samueli; Karen Nalbandyan; Daniel Benharroch; Itai Levi
Journal:  Acta Haematol       Date:  2021-11-09       Impact factor: 3.068

7.  LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.

Authors:  Shi-Dong Ma; Xuequn Xu; Julie Plowshay; Erik A Ranheim; William J Burlingham; Jeffrey L Jensen; Fotis Asimakopoulos; Weihua Tang; Margaret L Gulley; Ethel Cesarman; Jenny E Gumperz; Shannon C Kenney
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

Review 8.  The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification.

Authors:  Madhu P Menon; Stefania Pittaluga; Elaine S Jaffe
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

Review 9.  Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature.

Authors:  Shu-Mei Zheng; De-Jiang Zhou; Yi-Hua Chen; Rui Jiang; Yun-Xia Wang; Yong Zhang; Hong-Li Xue; Hai-Qiong Wang; Dong Mou; Wei-Zheng Zeng
Journal:  World J Gastroenterol       Date:  2017-06-28       Impact factor: 5.742

10.  First case of T-cell/histiocyte-rich-large B-cell lymphoma presenting with duodenal obstruction.

Authors:  Ali Riza Köksal; Huseyin Alkim; Meltem Ergun; Salih Boga; Mehmet Bayram; Canan Alkim; Ozlem Ton Eryilmaz
Journal:  Libyan J Med       Date:  2013-12-16       Impact factor: 1.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.